Investor Relations

The webinar features a presentation from Key Opinion Leader (KOL) Ezra Cohen, MD, FRCPSC, FASCO (Chief of Hematology/Oncology, Department of Medicine and Co-director of the Gleiberman Head and Neck Cancer Center, University of California, San Diego), who discusses the current treatment landscape in nasopharyngeal carcinoma (NPC) and the Viracta management team discusses the potential of Viracta’s all-oral combination product Nana-val (nanatinostat and valganciclovir) to address the unmet needs of NPC patients with EBV⁺ disease. A Q&A session follows the formal presentations. 

A link the webcast replay is here: https://lifesci.events/VIRX2